MV-NB-02, its bivalent ganglioside vaccine consisting of GD2-lactone and GD3-lactone each covalently conjugated to keyhole hemocyanin | |
---|---|
Trade Name | |
Orphan Indication | Neuroblastoma |
USA Market Approval | USA |
USA Designation Date | 2014-09-23 00:00:00 |
Sponsor | MabVax Therapeutics, Inc.;11588 Sorrento Road, Suite 20;San Diego, California, 92121 |
Related Access Program
South Plains Oncology Consortium – Recurrent Neuroblastoma
Catalyst Pharmaceuticals, Inc. – Downbeat Nystagmus
South Plains Oncology Consortium – Neuroblastoma
British Columbia Cancer Agency – Neuroblastoma
South Plains Oncology Consortium – Neuroblastoma
Children’s Hospital of Philadelphia – Neuroblastoma
University of California, San Francisco – Neuroblastoma
Jubilant DraxImage Inc. – Neuroblastoma
Children’s Hospital Medical Center, Cincinnati – Neuroblastoma
Apeiron Biologics AG – Neuroblastoma